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The Diabetes Control and Complications Trial 
(DCCT) showed that intensive diabetes treatment 
designed to achieve near-normoglycaemia sub-
stantially reduced the risk of progression and delayed 
the development of complications in patients with 
type 1 diabetes when compared with a conventional treatment 
approach.[1] The Epidemiology of Diabetes Interventions and 
Complications (EDIC) trial, a follow-on trial from the DCCT and 
‘clinical experience’, highlighted the difficulty of achieving and 
maintaining near-normoglycaemia in practice.[2] The challenge for 
healthcare professionals is to devise strategies that help patients to 
achieve and maintain glycaemic targets safely. Self-monitoring of 
blood glucose (SMBG) measurements and glycated haemoglobin 
(HbA1c) have become integral components of intensive diabetes 
management.[3,4] It is accepted that SMBG can improve compliance 
with recommendations on diet and exercise and assist with 
modification of insulin regimens, but some still question its value.[5]
There has been recent debate on the utility of SMBG in Washing-
ton State, USA, where the state attempted to limit the number 
of test strips supplied to do SMBG testing to one test per day 
in children.[5] However, after consideration it was decided that 
patients under 18 years of age with type 1 diabetes would be 
allowed funding for unlimited self-monitoring of blood sugars. 
This highlights the need for studies on the effectiveness of SMBG 
in a paediatric population with type 1 diabetes.
Evidence supporting SMBG would need to find a negative 
correlation between HbA1c and testing frequency. We analysed 
the relationship between insulin regimen, frequency of SMBG 
and glycaemic control measured by HbA1c in 141 paediatric and 
adolescent patients on our diabetes managed care programme.[6]
Methods
Rationale for selection of the study population
The advantage of using this managed care practice was the ability to 
quantify frequency of SMBG and blood glucose control accurately. 
Blood glucose test strip dispensing in the practice was tightly linked 
to the actual frequency of SMBG obtained from individual patients’ 
meter downloads at each visit, and the number of test strips dispensed 
per year was accurately recorded for each patient. A similar process 
was followed for insulin use, so that a very accurate estimate of daily 
insulin use could be obtained. Glycaemic control was measured by 
means of 3-monthly HbA1c level over the 1-year study period. Care 
was delivered by the same team over the observation period, the 
study population remained stable with no turnover of patients in the 
group, and all supplies were obtained from a single source. 
A total of 141 patients aged 2 - 18 years with type 1 diabetes were 
included in the retrospective analysis from 1 February 2010 to 30 
January 2011. To exclude the effect of the ‘honeymoon period’, only 
patients who had been diagnosed for >1 year were included. Patients 
were stratified according to the number of injections they received 
per day in their treatment regimen. Patients receiving premixed 
insulin twice daily were classified as being on a two injections per 
day regimen; if a lunchtime injection of bolus insulin was added they 
were classified as being on three injections per day. The remainder 
of the patients were receiving basal insulin at breakfast and dinner 
or bedtime and bolus insulin at major meals, and were classified 
as being on five injections per day. No patients were receiving four 
injections per day. Patients on continuous subcutaneous insulin 
infusion (CSII) therapy were classified separately. The number of 
SMBG measurements per day was analysed, as well as total daily dose 
of insulin and injection regimen. The mean of each patient’s HbA1c 
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over the study period was calculated from 
the average of their 3-monthly tests. All tests 
were performed on the same DCA Vantage 
Analyzer (Siemens Medical Solutions 
Diagnostics, USA).
Results
A total of 141 patients (74 male) were 
studied. The mean age was 11.7 years (range 
2 - 18), the mean duration of diabetes was 4.7 
years (range 1 - 12), and the mean amount 
of insulin used was 0.95 U/kg/d (range 
0.3 - 1.47). Nine patients were receiving two 
injections per day (6.3%), 19 three injections 
per day (13.5%), 49 five or more injections 
per day (34.8%), and 64 CSII (45.4%). 
Injection regimen
There was a highly significant decrease 
(p<0.0001) in HbA1c levels when comparing 
patients receiving two, three and five 
injections per day, but the difference in 
HbA1c levels between five injections per day 
and CSII was not significant (Fig. 1). The 
HbA1c standard deviations also differed 
significantly (p<0.0001) across the four 
groups, displaying the same pattern as the 
averages (Table 1). The HbA1c decreased as 
the number of injections per day increased. 
Frequency of testing per day
There was a highly significant decrease 
(p<0.001) in HbA1c levels as the frequency 
of testing increased, with an estimated 
average decrease of 0.34% per unit increase 
in the number of SMBG measurements per 
day (Fig. 2). Using analysis of covariance 
to correct for the simultaneous effect of 
the injection regimen, the average decrease 
in HbA1c was 0.19% per unit increase in 
SMBG measurements per day (p<0.001). 
Those on the two injections per day 
regimen performed on average 1.6 SMBG 
measurements per day, those on the three-
injection regimen 2.3 per day, those on five 
injections 4.3 per day, and those on CSII 5.2 
per day. In our cohort, patients achieving 
an  American Diabetes Association and 
International Society for Pediatric and 
Adolescent Diabetes target HbA1c level of 
<7.5% (International Federation of Clinical 
Chemistry 58 mmol/mol)[15] had a modal 
testing frequency of five tests per day, 
ranging from one to nine SMBG tests per 
day. 
Discussion
The goal of SMBG is to obtain useful infor-
mation with which to maintain and manage 
overall glucose status, with an ultimate goal 
of achieving ‘normo glycaemia’ and prevent-
ing the long-term complications associated 
with poor glycaemic control. There are two 
main reasons for obtaining blood glucose 
data. The first is to obtain immediate infor-
mation on the status of the blood glucose 
level, so that hypoglycaemia and hypergly-
caemia can be minimised through timely 
and meaningful interventions. The second is 
Table 1. HbA1c according to insulin regimen
Insulin regimen
2 injections/day 3 injections/day 5 injections/day CSII
Patients, n 9 19 49 64
HbA1c level (%), mean (SD) 10.59 (2.00) 10.02 (1.45) 8.24 (1.03) 8.09 (0.79)
SMBG measurements per day (n), mean (range) 1.6 (0.53 - 4.2) 2.3 (0.5 - 4.8) 4.3 (0.8 - 9.3) 5.2 (1.8 - 9.2)
SD = standard deviation.
2 inj. CSII5+ inj.3 inj.
p<0.0001
p<0.0001
























Fig. 2. Scatter plot comparing number of SMBG measurements v. HbA1c for all patients. 
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to obtain data for pattern analysis according to which meals can be 
planned, insulin dosages calculated and lifestyle adjustments made. 
Certain fundamental behaviours are associated with better 
glycaemic control,[7] such as the frequency of SMBG measurement,[8] 
frequency of insulin injections,[1] absence of insulin omission,[9] 
adherence to meal planning[10] and patient-initiated dose adjust-
ments.[11,12] These behaviours are the responsibility of each patient 
and caregiver, with non-adherence resulting in poor diabetic 
control.
SMBG is a painful, costly and onerous task that has become part 
and parcel of modern-day diabetes management. Numerous testing 
regimens exist, with little evidence to suggest superiority of one over 
another. To be beneficial, SMBG needs to be a ‘value add’ to the 
patient and the medical team. Often patients are not empowered 
to analyse their SMBG data or to adjust their insulin dosages. This 
disempowerment may lead to apathy, depression, and conflict within 
the family. Such patients see minimal benefit from testing, leading 
to a decline in actual testing frequency, and perhaps even data 
corruption and embellishment, so that an accurate picture of their 
glycaemic control becomes impossible to obtain.[13]
To the healthcare professional, accurate SMBG data are a valuable 
aid to the clinical assessment on the basis of which treatment 
adjustments can be recommended. Other studies support a 
correlation between frequency of testing and HbA1c reduction.[8,14] 
Our study supports these findings, showing a 0.19% improvement 
in HbA1c per unit increase in the number of SMBG measurements 
performed per day after correcting for the injection regimen.
One of the limitations of this study is the interdependence of 
testing frequency and injection regimen. Both the injection regimen 
and testing frequency influenced the HbA1c. However, analysis of 
covariance continued to show that testing frequency had a highly 
significant negative effect on the HbA1c in this study (p=0.0002). 
Patients receiving fixed dosages of premixed insulin (i.e two- or 
three-injection regimen) often perform fewer SMBG measurements. 
There are two possible explanations for this: patients who volunteer 
for less intensive regimens such as fixed-dosage premixed insulin 
also opt to perform fewer SMBG tests per day; and fewer SMBG 
measurements are required in the day-to-day management of glucose 
control on this two- or three-injection regimen than on a more 
intensive regimen of five injections per day.
On more intensive regimens, in particular on CSII therapy, 
patients are preselected according to their ability to perform multiple 
SMBG measurements a day, and are required to do so to verify the 
integrity of the pump function in terms of insulin delivery. The 
only group in which the testing frequency is less influenced by the 
injection regimen is the five injections per day group. Sub-analysis of 
this group using regression analysis still found a significant negative 
correlation between frequency of SMBG measurement and HbA1c 
(p=0.001). 
SMBG provides data in the form of an output variable that is a 
summation of a number of input variables such as insulin dose, 
insulin type, carbohydrate load and exercise. An increase in testing 
frequency allows for multiple hypotheses to be tested. The cycle of 
testing and modification of the input variables strives through each 
iteration to achieve predictable and desirable glycaemic outcomes. 
Finding the perfect testing frequency and intensity is a subject of 
ongoing research.
Overall, the study revealed a positive inverse relationship between 
frequency of SMBG measurements per day and HbA1c after 
correcting for the insulin regimen.
Conclusion
SMBG is essential for monitoring daily glycaemic control and for 
detecting and acutely managing hyper- and hypoglycaemic episodes. 
It also provides data for pattern analysis that can be used to reinforce 
positive behaviours and reduce negative ones. SMBG analysis assists 
in meal planning and dosage adjustment, and in so doing minimises 
glycaemic variability and allows patients to obtain recommended 
HbA1c targets. A clear beneficial relationship exists between the 
frequency of SMBG measurements performed per day and a lower 
HbA1c in paediatric patients with type 1 diabetes. While a tailored 
approach is required for each patient, restricted access to SMBG test 
strips should not be allowed to handicap a patient’s diabetes control 
efforts. 
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